Featured

Status

Health Topics

Any Category
Diseases
Nervous System Diseases
Clear Filters

Search Clinical Trials

20 Results
Completed
Aggression Prevention Training for Caregivers of Persons With Dementia (APT)
Eighty percent of PWD have behavioral or psychological disturbances, including 40% that are aggressive behaviors. The prevalence of pain in PWD is about 60%, and it is a strong predictor …
Baylor Role: Lead Sponsor
Completed
MER Versus MRI Guidance DBS in Parkinson's Disease
Patients who have been randomized into Group 1 will undergo DBS implantation while awake. On the morning of surgery, the patient will undergo placement of the stereotactic head frame under …
Baylor Role: Lead Sponsor
Completed
Amitiza in Constipation Associated With PD (Parkinson's Disease)
Parkinson's disease (PD) affects about one million people in the United States. It is a common neurological condition that is clinically defined by rigidity (muscle stiffness), bradykinesia (slowness of movement) …
Baylor Role: Lead Sponsor
Completed
Selegiline to Zelapar Switch Study in Parkinson Disease Patients
This is an open label, multicenter, 6 week study of the conversion from oral selegiline to orally disintegrating selegiline in PD patients with or without motor fluctuations, and currently taking …
Baylor Role: Lead Sponsor
Completed
Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study
This is a study to compare orally dissolving levodopa (Parcopa) to the conventional immediate release oral levodopa. This is a single-dose, double-blind, placebo controlled crossover trial in participants with Parkinson …
Baylor Role: Lead Sponsor
Withdrawn
Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease
The purpose of this study is to determine how many patients with Parkinson's disease have compulsive behaviors, and what types of behaviors they have. This study will also determine if …
Baylor Role: Lead Sponsor
Completed
Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Patients were enrolled over 11 months from the Parkinson Disease Center and Movement Disorder Clinic at Baylor College of Medicine. PD was diagnosed using standard criteria. Specific inclusion criteria were …
Baylor Role: Lead Sponsor
Completed
An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
In order to enroll in this study, you must have completed the Double-Blind phase of CAPSS-176 or discontinued the Double-Blind phase of CAPSS-176 after a minimum of 6 weeks because …
Baylor Role: Lead Sponsor
Completed
A Randomized, Placebo-controlled, Tourette Syndrome Study.
This study consists of three phases: Screening/Washout Phase, Double-Blind Phase and Taper Phase. SCREENING/WASHOUT PHASE: Your study doctor or his staff will review with you any medications that you are …
Baylor Role: Lead Sponsor
Completed
Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)
Inclusion required an Epworth Sleepiness Scale (ESS) score greater than 10 and any subjective nocturnal sleep concern, usually insomnia. An acclimation and screening polysomnogram was performed to exclude subjects with …
Baylor Role: Lead Sponsor